HIV-1 Latency Reversal Agent Boosting Is Not Limited by Opioid Use

The authors studied forty-seven virally suppressed people with HIV and observed that lower concentration of HIV-1 latency reversal agents, used in combination with small molecules that did not reverse latency, synergistically increased the magnitude of HIV-1 re-activation ex vivo, regardless of opioid use.